According to previous studies, the loss or mutation in CDKN2A leads to uncontrolled cancer cell proliferation, while TP53 mutations are associated with CDKN2A mutations and high tumor mutational burden (19, 20). The gene discussed is CDKN2A; the disease is neoplasm.